Short Interest in Co-Diagnostics, Inc. (NASDAQ:CODX) Expands By 9.8%

Co-Diagnostics, Inc. (NASDAQ:CODX) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 229,100 shares, an increase of 9.8% from the October 31st total of 208,700 shares. Based on an average daily trading volume, of 127,300 shares, the days-to-cover ratio is presently 1.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.50 price target on shares of Co-Diagnostics in a research note on Monday, November 11th.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. Jane Street Group LLC purchased a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned approximately 0.14% of Co-Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 14.99% of the company’s stock.

Co-Diagnostics Price Performance

Shares of NASDAQ:CODX traded up $0.01 during trading on Wednesday, reaching $0.89. 58,242 shares of the stock were exchanged, compared to its average volume of 139,163. The stock has a fifty day moving average of $1.16 and a two-hundred day moving average of $1.24. Co-Diagnostics has a 1-year low of $0.85 and a 1-year high of $2.23. The firm has a market cap of $28.42 million, a price-to-earnings ratio of -0.64 and a beta of -0.91.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.